-
EHDN 2026 Part 1: What’s next in the Huntington’s disease treatment pipeline?
9 min read
Latest News
-
Skyhawk’s drug trial takes flight in the US
4 min read
Skyhawk’s FALCON-HD trial has dosed the first participants in the US with the drug, SKY-0515. The once-daily pill targets two drivers of HD, but does it actually slow disease? That’s the big question this study hopes to answer.
-
HD mice provide a useful failure
5 min read
Can drug trials that fail be helpful? A HD mouse study provides solid evidence of an approach that doesn't help HD
-
Illuminating the progression of Huntington’s disease
6 min read
Researchers have used mice with glowing brain cells to decipher the first steps of neurodegeneration
-
Jumping genes: Huntington's disease protein invades brain transplants
6 min read
A long-term study of the brains of HD patients who received grafts of fetal tissue reveals a surprising result
-
The brain in Huntington's disease: greater than the sum of its parts?
6 min read
An important new study asks the question: what parts of the brain might need most help in HD?
-
NUB1: enhancing clearance to decrease mutant huntingtin
5 min read
NUB1 increases mutant huntingtin removal from cells, reducing the toxic effects of HD in fruit flies
-
Could HD be caused by amino acid deficiency?
7 min read
Does a specific amino acid deficiency contribute to the development of HD?
-
Raptor announces results of cysteamine trial for Huntington's disease
10 min read
Raptor Pharmaceuticals announces intermediate results from a long-term study of cysteamine in Huntington's disease
-
Sleep, cilia and HD
9 min read
New studies shed some light on the function of sleep in animals, with interesting implications for HD research
-
Huntington's Disease Therapeutics Conference 2014: day 3
8 min read
Biomarkers and preparing for trials: the third & final day of the 2014 Huntington's Disease Therapeutics Conference
-
Huntington's Disease Therapeutics Conference 2014: day 2
5 min read
Cells, circuits and systems: day 2 of the 2014 HD Therapeutics conference
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
